Clariant Opens New Innovation Center in Frankfurt
Clariant opens its new Clariant Innovation Center in Germany, a hub for R&D research.
Clariant, a provider of fine and specialty chemicals, has opened its new EUR 100 million ($134 million) Clariant Innovation Center (CIC) in Frankfurt, Germany. The company’s new global hub for R&D is based at the “Industriepark Höchst.” It will be the home of Clariant’s competence centers in chemical research and process technology as well as application laboratories for several business units and analytical laboratories. The CIC will also house the departments for Intellectual Property Management and New Business Development. As the corporation’s global hub, the CIC will coordinate Clariant’s R&D network, which includes centers across Europe, North America, Brazil, Japan, India, and China. The new facility covers a total surface area of 36,000 m2 and will house around 500 employees from R&D and support business and administrative functions. It features a mix of open workspaces, offices, and laboratories.
Source: Clariant
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
